Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Teva Preps For SD-809 Tardive Dyskinesia Filing By The End Of 2016

Executive Summary

A second Phase III study testing the VMAT2 inhibitor in the indication was positive, positioning Teva for a neck-and-neck race to market against Neurocrine.

Advertisement

Related Content

Neurocrine Beats Teva To Tardive Dyskinesia Market With Ingrezza
Keeping Track: Xermelo, Odactra, Noctiva Approved; Second Submissions For Avelumab And Deutetrabenazine
Neurocrine Eyes June Launch Date For Valbenazine In Tardive Dyskinesia
Keeping Track: Oncology Approvals And Responses To Complete Response Letters
Neurocrine Gets First Drug For Tardive Dyskinesia To FDA
Teva CRL Response For Huntington’s Drug Targeted For September
Pressure off Teva's CNS hopes as tardive dyskinesia drug succeeds
Teva Makes A Specialty M&A Play In Deal To Buy Auspex

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097345

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel